Company: TELO
Filing Date: 2025-10-06
Form Type: 8-K
Source: 0001493152-25-017072
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-10-06
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor
Genes Implicated in Two of the Most Persistent Challenges in Oncology - Metastasis and Treatment Resistance

Findings
show that Telomir-1 restores the body’s natural tumor suppressor defenses by reversing abnormal DNA methylation of MASPIN and RASSF1A
 - genes that help block invasion, limit metastasis, and improve chemotherapy responsiveness in aggressive prostate cancer models.

On
October 6, 2025, Telomir Pharmaceuticals, Inc. (the “ Company”) announced new cancer results

The
studies demonstrated that Telomir-1 resets abnormal DNA methylation to restore the function of two additional critical tumor suppressor
genes - MASPIN and RASSF1A. metastasis
and treatment resistance

  MASPIN                        

MASPIN
is a natural defense protein that blocks tumor invasion, regulates cell migration and angiogenesis, promotes apoptosis, and enhances
treatment sensitivity. In an aggressive prostate-cancer model in vivo, MASPIN was silenced by DNA hypermethylation. Telomir-1 reversed
the chemotherapy-induced DNA methylation to restore MASPIN activity, consistent with reactivation of this key tumor-suppressor pathway.

  RASSF1A                                   

RASSF1A
is a critical regulator of cell cycle brakes, apoptosis, and suppression of metastasis. It is commonly silenced in aggressive cancers
by hypermethylation. Telomir-1 reduced RASSF1A methylation in a dose-dependent manner, with stronger effects when combined with chemotherapy.

  Implication: These results suggest Telomir-1 may reactivate natural tumor defenses, counteract chemotherapy-induced  
  resistance mechanisms, and help limit metastasis — two of the most persistent challenges                             
  in oncology.                                                                                                         
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

By
reactivating MASPIN and RASSF1A through DNA methylation reset, Telomir-1 expands the potential to restore natural tumor defenses,
counteract chemotherapy-induced resistance, and help limit cancer metastasis.

The
Company is continuing its preclinical development of Telomir-1 and is currently advancing the program with IND-enabling studies.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 193